Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Apricus Biosciences Announces Closing Of Finesco-Scomedica Transaction

RELATED NEWS
Trade APRI now with 
7/13/2012 12:56 PM ET

Apricus Biosciences, Inc. (APRI: Quote) announced the closing of its agreement to own Finesco, by way of a share contribution.

Finesco is the French parent and holding company of Scomedica, a leading French healthcare contract sales and marketing organization.

Apricus said that Finesco and Scomedica will operate as wholly-owned subsidiaries of Apricus Bio.

The company stated that under the terms of the agreement, Finesco's existing shareholders contributed to Apricus Bio 100% of the outstanding common stock of Finesco in exchange for 2.6 million newly issued shares of Apricus Bio common stock valued at EURO7 million or US$8.8 million at the closing.

In addition, newly issued shares worth about EURO1.8 or US$2.3 million are due in the first quarter of 2013 if Scomedica achieves certain revenue milestones during 2012, Apricus Bio noted.

Click here to receive FREE breaking news email alerts for Apricus Biosciences, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Design software maker Autodesk, Inc. (ADSK) Thursday reported a 30 percent decline in earnings from last year, hurt by lower revenue and weaker margins. The company's quarterly earnings per share, excluding items, came in below analysts' expectations as did its quarterly revenue. At the same time,... Struggling PC maker Dell Inc. said Thursday after the markets closed that its first quarter profit dropped 79% from last year, as revenue declined and margins deteriorated amid sluggish demand for personal computers. The company's quarterly earnings per share, excluding items, also came in way below analysts' expectations, but its quarterly revenue beat analysts' forecast. Cisco Systems, Inc., the world's largest computer networking gear maker, said Wednesday after the markets closed that its third quarter profit rose 14.5% from last year, helped by higher sales and a tax benefit. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly sales.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.